title: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
abstract: Somatostatin receptor scintigraphy (SRS) has been used for the detection of gastroenteropancreatic (GEP) tumors. This study evaluates the clinical impact of SRS in GEP tumor detection and its therapeutic implications on patient management.
  
  
  METHODS
  We prospectively studied 160 patients with biologically and/or histologically proven GEP tumors. Before SRS, patients were classified into three groups: gastrointestinal (Group 1; n = 90) patients without known metastases; (Group 2; n = 59) patients with metastases limited to the liver; (Group 3; n = 11) patients with known extrahepatic metastases. The scintigraphic data were compared to the radiological findings.
  
  
  RESULTS
  In Group 1, without known metastases, conventional imaging detected 53 primary sites in 44 patients: SRS was positive in 68% of these sites and discovered 4 additional primary tumors in 3 patients and 16 metastases in 14 patients. Conventional imaging was negative in 46 patients: SRS discovered 47 new sites in 36 patients. In Group 2, SRS confirmed liver metastases in 95% of patients and discovered 45 new sites in 36 of these patients. In Group 3, SRS disclosed 11 new sites in 7 patients. These results modified patient classification in 38 cases (24%). Surgical therapeutic strategy was changed in 40 patients (25%).
  
  
  CONCLUSIONS
  Somatostatin receptor scintigraphy improves tumor detection, has major clinical significance and should be performed systematically for staging and therapeutic decision making in patients with GEP tumors.
authors.affiliation: Department of Nuclear medicine, Hôpital Bichat, Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Lebtahi
authors.forename: G
authors.initials: G
authors.lastname: Cadiot
authors.forename: L
authors.initials: L
authors.lastname: Sarda
authors.forename: D
authors.initials: D
authors.lastname: Daou
authors.forename: M
authors.initials: M
authors.lastname: Faraggi
authors.forename: Y
authors.initials: Y
authors.lastname: Petegnief
authors.forename: M
authors.initials: M
authors.lastname: Mignon
authors.forename: D
authors.initials: D
authors.lastname: le Guludec
mesh_terms: D002276:Carcinoid Tumor / Q000000981:diagnostic imaging* / Q000556:secondary; D016022:Case-Control Studies; D003952:Diagnostic Imaging; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging*; D006801:Humans; D007205:Indium Radioisotopes; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000556:secondary; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging*; D011446:Prospective Studies; D017481:Receptors, Somatostatin / Q000032:analysis*; D012680:Sensitivity and Specificity; D013004:Somatostatin / Q000031:analogs & derivatives*; D015899:Tomography, Emission-Computed, Single-Photon; D015043:Zollinger-Ellison Syndrome / Q000000981:diagnostic imaging*
chemical_list: D007205:Indium Radioisotopes; D017481:Receptors, Somatostatin; D013004:Somatostatin; C081788:pentetreotide